Generated September 2026 · Clinical Deep Dive 0 Comments Ipilimumab is a human IgG1 antibody. Tremelimumab is IgG2. That single digit is not a footnote. IgG1 binds activating Fc-gamma receptors far more readily than IgG2, and in preclinical models that difference is what lets ipilimumab-type antibodies deplete CTLA-4-high regulatory T cells inside a tumor…
Read More
Deep Dive: CTLA-4 Inhibitors: One Target, Two Antibody Designs
